Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples: Protocol to Validate the Sufficiency of Provider-Observed, Home-Collected Blood, Saliva, and Oropharyngeal Samples

Patrick Sean Sullivan, Charles Sailey, Jodie Lynn Guest, Jeannette Guarner, Colleen Kelley, Aaron Julius Siegler, Mariah Valentine-Graves, Laura Gravens, Carlos Del Rio, Travis Howard Sanchez, Patrick Sean Sullivan, Charles Sailey, Jodie Lynn Guest, Jeannette Guarner, Colleen Kelley, Aaron Julius Siegler, Mariah Valentine-Graves, Laura Gravens, Carlos Del Rio, Travis Howard Sanchez

Abstract

Background: The response in the United States to the coronavirus disease (COVID-19) pandemic has been hampered by a lack of aggressive testing for the infection. Testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cornerstone of an effective public health response. However, efforts to test have been hampered by limited reagents, limitations in the availability of swabs used for the collection of nasopharyngeal swab (NPS) specimens, limitations in personal protective equipment (PPE) for health care providers collecting the NPS specimens, and limitations in viral transport media for transporting the specimens. Therefore, more flexible options for screening for SARS-CoV-2 RNA and serologic responses are critical to inform clinical and public health responses.

Objective: We aim to document the ability of patients to self-collect sufficient specimens for SARS-CoV-2 viral detection and serology.

Methods: Patient self-collection of samples will be done with observation by a health care provider during a telemedicine session. Participants will be mailed a specimen collection kit, engage in a telehealth session with a provider through a HIPPA (Health Insurance Portability and Accountability Act of 1996)-compliant video meeting, and collect specimens while being observed by the provider. Providers will record whether they are confident in the suitability of the specimen for laboratory testing that would inform clinical decision making. We will objectively assess the sufficiency of biological material in the mailed-in specimens.

Results: The protocol was approved by the Emory University Institutional Review Board (IRB) on March 30, 2020 (Protocol number 371). To date, we have enrolled 159 participants.

Conclusions: Defining a conceptual framework for assessing the sufficiency of patient-collected samples for the detection of SARS-CoV-2 RNA and serologic responses to infection is critical for facilitating public health responses and providing PPE-sparing options to increase testing. Validation of alternative methods of specimen collection should include objective measures of the sufficiency of specimens for testing. A strong evidence base for diversifying testing modalities will improve tools to guide public health responses to the COVID-19 pandemic.

Keywords: COVID-19; PCR; RNA-PCR; SARS-CoV-2; diagnostic; infectious disease; outbreak; public health; serology; telemedicine; testing.

Conflict of interest statement

Conflicts of Interest: TS is editor-in-chief of JMIR Public Health and Surveillance. Because of this, he was not involved in the editorial handling or peer-review of this paper.

©Patrick Sean Sullivan, Charles Sailey, Jodie Lynn Guest, Jeannette Guarner, Colleen Kelley, Aaron Julius Siegler, Mariah Valentine-Graves, Laura Gravens, Carlos del Rio, Travis Howard Sanchez. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 24.04.2020.

Figures

Figure 1
Figure 1
Participant instructions for self-collection via oropharyngeal swab.
Figure 2
Figure 2
Participant instructions for self-collection of dried blood spots.
Figure 3
Figure 3
Participant instructions for self-collection of saliva.

References

    1. World Health Organization. 2020. [2020-03-31]. Coronavirus disease 2019 (COVID-19): situation report, 51 .
    1. Watkins J. Preventing a covid-19 pandemic. BMJ. 2020 Feb 28;368:m810. doi: 10.1136/bmj.m810.
    1. Goldstein N, Burstyn I. On the importance of early testing even when imperfect in a pandemic such as COVID-19. Preprint. 2020 Mar; doi: 10.31219/.
    1. Adalja AA, Toner E, Inglesby TV. Priorities for the US Health Community Responding to COVID-19. JAMA. 2020 Mar 03; doi: 10.1001/jama.2020.3413.
    1. Rimmer A. Covid-19: BMA calls for rapid testing and appropriate protective equipment for doctors. BMJ. 2020 Mar 17;368:m1099. doi: 10.1136/bmj.m1099.
    1. Baird R. The New Yorker. 2020. Mar 16, [2020-04-23]. What went wrong with Coronavirus testing in the US? .
    1. Binnicker M. Emergence of a Novel Coronavirus Disease (COVID-19) and the Importance of Diagnostic Testing: Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak. Clin Chem. 2020 Feb 20;:2020. doi: 10.1093/clinchem/hvaa071.
    1. Centers for Disease Control and Prevention. 2020. Apr 16, [2020-04-23]. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19) .
    1. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. Corrigendum to "World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19)" [Int J Surg 76 (2020) 71-76] Int J Surg. 2020 Apr 15; doi: 10.1016/j.ijsu.2020.03.036.
    1. Webber L, Jewett C. . 2020. Mar 18, [2020-03-25]. Testing Swabs Run In Short Supply As Makers Try To Speed Up Production online news report .
    1. McMichael T, Clark Shauna, Pogosjans Sargis, Kay Meagan, Lewis James, Baer Atar, Kawakami Vance, Lukoff Margaret D, Ferro Jessica, Brostrom-Smith Claire, Riedo Francis X, Russell Denny, Hiatt Brian, Montgomery Patricia, Rao Agam K, Currie Dustin W, Chow Eric J, Tobolowsky Farrell, Bardossy Ana C, Oakley Lisa P, Jacobs Jesica R, Schwartz Noah G, Stone Nimalie, Reddy Sujan C, Jernigan John A, Honein Margaret A, Clark Thomas A, Duchin Jeffrey S, Public Health – Seattle & King County‚ EvergreenHealth‚ CDC COVID-19 Investigation Team COVID-19 in a Long-Term Care Facility - King County, Washington, February 27-March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339–342. doi: 10.15585/mmwr.mm6912e1. doi: 10.15585/mmwr.mm6912e1.
    1. World Health Organization. 2020. [2020-04-22]. Rational use of personal protective equipment for coronavirus disease (COVID-19): interim guidance, 27 February 2020 .
    1. Jones PM. FDA regulation of LDTs--an update. MLO Med Lab Obs. 2015 Sep;47(9):18–9.
    1. Caliendo AM, Hanson KE. Point-Counterpoint: The FDA Has a Role in Regulation of Laboratory-Developed Tests. J Clin Microbiol. 2016 Jan 20;54(4):829–833. doi: 10.1128/jcm.00063-16.
    1. US Food and Drug Administration. 2020. [2020-03-25]. Coronavirus (COVID-19) Update: FDA Provides More Regulatory Relief During Outbreak, Continues to Help Expedite Availability of Diagnostics [FDA statement] .
    1. UnitedHealth Group. 2020. Mar 25, [2020-04-23]. UnitedHealth Group Study Clears Path for Self-Administered COVID-19 Test, Improving Testing Efficiency and Protecting Health Care Workers .
    1. Branson BM. Home sample collection tests for HIV infection. JAMA. 1998 Nov 18;280(19):1699–701. doi: 10.1001/jama.280.19.1699.
    1. Hobbs MM, van der Pol B, Totten P, Gaydos CA, Wald A, Warren T, Winer RL, Cook RL, Deal CD, Rogers ME, Schachter J, Holmes KK, Martin DH. From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections. Sex Transm Dis. 2008 Jan;35(1):8–13. doi: 10.1097/OLQ.0b013e31815d968d.
    1. Gaydos CA. Let's Take A "Selfie": Self-Collected Samples for Sexually Transmitted Infections. Sex Transm Dis. 2018 Apr;45(4):278–279. doi: 10.1097/OLQ.0000000000000785.
    1. To KK-W, Tsang O, Chik-Yan Yip Cyril, Chan K, Wu T, Chan J, Leung Wai-Shing, Chik Thomas Shiu-Hong, Choi Chris Yau-Chung, Kandamby Darshana H, Lung David Christopher, Tam Anthony Raymond, Poon Rosana Wing-Shan, Fung Agnes Yim-Fong, Hung Ivan Fan-Ngai, Cheng Vincent Chi-Chung, Chan Jasper Fuk-Woo, Yuen Kwok-Yung. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020 Feb 12;:2020. doi: 10.1093/cid/ciaa149.
    1. Fernandes-Monteiro AG, Trindade GF, Yamamura AMY, Moreira OC, de Paula VS, Duarte ACM, Britto C, Lima SMB. New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters. Hum Vaccin Immunother. 2015;11(7):1865–71. doi: 10.4161/21645515.2014.990854.
    1. MacGowan RJ, Chavez PR, Gravens L, Wesolowski LG, Sharma A, McNaghten AD, Freeman A, Sullivan PS, Borkowf CB, Michele Owen S, eSTAMP Study Group Pilot Evaluation of the Ability of Men Who Have Sex with Men to Self-Administer Rapid HIV Tests, Prepare Dried Blood Spot Cards, and Interpret Test Results, Atlanta, Georgia, 2013. AIDS Behav. 2018 Jan;22(1):117–126. doi: 10.1007/s10461-017-1932-1.
    1. Malosh R, Petrie J, Callear A, Monto A, Martin E. Home collection of nasal swabs for detection of influenza in the Household Influenza Vaccine Evaluation Study. medRxiv. 2020 doi: 10.1101/2020.03.24.20042556.
    1. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 — Studies Needed. N Engl J Med. 2020 Mar 26;382(13):1194–1196. doi: 10.1056/nejmp2002125.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel